Mouse Monoclonal CMTM6 Antibody

+ +

•  

   
     Western blot analysis using CMTM6 mouse mAb against  Jurkat lysate    

•  

   
     Lane 1: Jurkat lysate;  Lane 2: CMTM6 immunoprecipitated from Jurkat lysate by P15334;  Lane 3: The same as Lane 2 but use IgG isotype control antibody;Result: P15334 can immunoprecipitate CMTM6;    

•  

   
     IHC-P analysis of endometrium tissue by CMTM6 antibody (P15334) Immunohistochemistry was performed using sections of formalin-fixed paraffin- embedded endometrium tissue;Result: Glandular cells are positively stained at the cell membrane.    

CMTM6 (CKLF-like MARVEL transmembrane domain-containing 6) is a member of the chemokine-like factor (CKLF) superfamily, characterized by MARVEL domains implicated in membrane-associated processes. It has gained attention for its role in regulating immune checkpoint proteins, particularly PD-L1 (programmed death-ligand 1). Studies show CMTM6 stabilizes PD-L1 on the cell surface by preventing its lysosomal degradation, thereby modulating tumor immune evasion. This interaction positions CMTM6 as a critical player in cancer immunology and a potential therapeutic target.

CMTM6 antibodies are essential tools for investigating its expression, localization, and functional mechanisms. They enable detection via techniques like Western blot, immunohistochemistry, and flow cytometry, aiding research into its role in tumor microenvironments and immune response regulation. Elevated CMTM6 expression correlates with poor prognosis in cancers such as melanoma, lung cancer, and glioblastoma, linking it to disease progression and resistance to anti-PD-1/PD-L1 therapies.

Research using CMTM6 antibodies also explores its broader biological roles beyond oncology, including immune cell signaling and membrane protein trafficking. However, challenges remain in understanding its precise molecular interactions and tissue-specific functions. These antibodies are pivotal for developing strategies to disrupt CMTM6-PD-L1 binding, potentially enhancing immunotherapy efficacy. Overall, CMTM6 antibodies serve as vital reagents in both basic research and translational studies aiming to decode immune evasion mechanisms and improve cancer treatments.